Learn more about Hexima’s technology.


Hexima is conducting a phase I/IIa clinical trial of its lead antifungal molecule, HXP124, as a treatment for fungal nail infections.

Latest news

Hexima announces appointment of Michael Aldridge

Hexima Limited is pleased to announce the appointment of Mr Michael Aldridge as Chief Business Officer and a member of the Board of Directors, effective 21 May 2019. Mr Aldridge will be based in San Francisco, focussing on business development and establishing...

Mr Scott Robertson appointed to Board of Directors

Hexima Limited has announced the appointment of Mr Scott Robertson to its Board of Directors, effective 21 November 2018. Speaking at Hexima’s recent AGM, Chairman Professor Jonathan West said “I am pleased to announce today that we will be adding Mr Scott Robertson...

AGM 2018 – Presentation and Results

Presentations and Results from the 2018 Hexima Limited Annual General Meeting held 20 November 2018. AGM 2018 Chairman’s Address AGM 2018 CEO & CSO Presentation AGM 2018 Meeting Results

External Links

Take a look at these useful links to learn more about our industry.

Australian Academy of Science
Australian Science Media Centre logo